ArticleBlood2012
Efficient generation, purification, and expansion of CD34(+) hematopoietic progenitor cells from nonhuman primate-induced pluripotent stem cells.
Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 30 citations in OpenAlex.
- Acute High Intensity Interval Exercise Promotes Circulating Progenitor Cell Mobilization and Improves Microcirculation in Patients with Chronic Heart Failure.Journal of cardiovascular development and disease · 2026Article
- Antifragile Treatment for Efficient Chimerism of Induced Pluripotent Stem Cells Derived Hematopoietic Stem Cells.Stem cell reviews and reports · 2025Article
- CD34 Protein: Its expression and function in inflammation.Cell and tissue research · 2023Review
- StemRegenin 1 Mitigates Radiation-Mediated Hematopoietic Injury by Modulating Radioresponse of Hematopoietic Stem/Progenitor Cells.Biomedicines · 2023Article
- Prostaglandin EStem cell reviews and reports · 2021Article
- Generation of macrophages with altered viral sensitivity from genome-edited rhesus macaque iPSCs to model human disease.Molecular therapy. Methods & clinical development · 2021Article
- Natural estrogens enhance the engraftment of human hematopoietic stem and progenitor cells in immunodeficient mice.Haematologica · 2021Article
- Genetically edited CD34Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Large-scale generation of megakaryocytes from human embryonic stem cells using transgene-free and stepwise defined suspension culture conditions.Cell proliferation · 2021Article
- Reducing TGF-β1 cooperated with StemRegenin 1 promoted the expansion ex vivo of cord blood CD34Cell proliferation · 2021Article
- Isoform-specific involvement of Brpf1 in expansion of adult hematopoietic stem and progenitor cells.Journal of molecular cell biology · 2020Article
- MISTRG mice support engraftment and assessment of nonhuman primate hematopoietic stem and progenitor cells.Experimental hematology · 2019Article
- Prostaglandin E2 promotes human CD34+ cells homing through EP2 and EP4 in vitro.Molecular medicine reports · 2017Article
- Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells.Blood · 2017Article
- StemRegenin 1 selectively promotes expansion of Multipotent Hematopoietic Progenitors derived from Human Embryonic Stem Cells.Journal of stem cells & regenerative medicine · 2017Article
- GSK3β Inhibition Promotes Efficient Myeloid and Lymphoid Hematopoiesis from Non-human Primate-Induced Pluripotent Stem Cells.Stem cell reports · 2016Article
- Hematopoietic stem cell expansion and generation: the ways to make a breakthrough.Blood research · 2015Review
- From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Review
- The RUNX1 +24 enhancer and P1 promoter identify a unique subpopulation of hematopoietic progenitor cells derived from human pluripotent stem cells.Stem cells (Dayton, Ohio) · 2015Article
- Vascular niche promotes hematopoietic multipotent progenitor formation from pluripotent stem cells.The Journal of clinical investigation · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Induced pluripotent stem cell (iPSC) therapeutics are a promising treatment for genetic and infectious diseases. To assess engraftment, risk of neoplastic formation, and therapeutic benefit in an autologous setting, testing iPSC therapeutics in an appropriate model, such as the pigtail macaque (Macaca nemestrina; Mn), is crucial. Here, we developed a chemically defined, scalable, and reproducible specification protocol with bone morphogenetic protein 4, prostaglandin-E2 (PGE2), and StemRegenin 1 (SR1) for hematopoietic differentiation of Mn iPSCs. Sequential coculture with bone morphogenetic protein 4, PGE2, and SR1 led to robust Mn iPSC hematopoietic progenitor cell formation. The combination of PGE2 and SR1 increased CD34(+)CD38(-)Thy1(+)CD45RA(-)CD49f(+) cell yield by 6-fold. CD34(+)CD38(-)Thy1(+)CD45RA(-)CD49f(+) cells isolated on the basis of CD34 expression and cultured in SR1 expanded 3-fold and maintained this long-term repopulating HSC phenotype. Purified CD34(high) cells exhibited 4-fold greater hematopoietic colony-forming potential compared with unsorted hematopoietic progenitors and had bilineage differentiation potential. On the basis of these studies, we calculated the cell yields that must be achieved at each stage to meet a threshold CD34(+) cell dose that is required for engraftment in the pigtail macaque. Our protocol will support scale-up and testing of iPSC-derived CD34(high) cell therapies in a clinically relevant nonhuman primate model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.